These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27608608)

  • 1. Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience.
    Kanal E
    Magn Reson Imaging; 2016 Dec; 34(10):1341-1345. PubMed ID: 27608608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain gadolinium deposition after administration of gadolinium-based contrast agents.
    Kanda T; Oba H; Toyoda K; Kitajima K; Furui S
    Jpn J Radiol; 2016 Jan; 34(1):3-9. PubMed ID: 26608061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
    Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
    Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive Effect of Changing Contrast Media in Patients With A Prior Mild Immediate Hypersensitivity Reaction to Gadolinium-Based Contrast Agent.
    Ryoo CH; Choi YH; Cheon JE; Yoon SH; Kang HR; Park SJ; Lee W
    Invest Radiol; 2019 Oct; 54(10):633-637. PubMed ID: 31033674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI.
    Costelloe CM; Amini B; Madewell JE
    Semin Ultrasound CT MR; 2020 Apr; 41(2):170-182. PubMed ID: 32446430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.
    Holowka S; Shroff M; Chavhan GB
    Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
    Kuo PH
    J Am Coll Radiol; 2008 Jan; 5(1):29-35. PubMed ID: 18180006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are some agents less likely to deposit gadolinium in the brain?
    Radbruch A
    Magn Reson Imaging; 2016 Dec; 34(10):1351-1354. PubMed ID: 27629022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.
    Do C; DeAguero J; Brearley A; Trejo X; Howard T; Escobar GP; Wagner B
    Kidney360; 2020 Jun; 1(6):561-568. PubMed ID: 34423308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadolinium deposition in the brain.
    Kanda T; Nakai Y; Oba H; Toyoda K; Kitajima K; Furui S
    Magn Reson Imaging; 2016 Dec; 34(10):1346-1350. PubMed ID: 27613998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.
    Schieda N; Maralani PJ; Hurrell C; Tsampalieros AK; Hiremath S
    Can Assoc Radiol J; 2019 Aug; 70(3):226-232. PubMed ID: 31255393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadolinium-based contrast agents in pediatric magnetic resonance imaging.
    Gale EM; Caravan P; Rao AG; McDonald RJ; Winfeld M; Fleck RJ; Gee MS
    Pediatr Radiol; 2017 May; 47(5):507-521. PubMed ID: 28409250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium retention in the body: what we know and what we can do.
    Tedeschi E; Caranci F; Giordano F; Angelini V; Cocozza S; Brunetti A
    Radiol Med; 2017 Aug; 122(8):589-600. PubMed ID: 28361260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadolinium Deposition and Chronic Toxicity.
    Ramalho J; Ramalho M
    Magn Reson Imaging Clin N Am; 2017 Nov; 25(4):765-778. PubMed ID: 28964466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI contrast agents: basic chemistry and safety.
    Hao D; Ai T; Goerner F; Hu X; Runge VM; Tweedle M
    J Magn Reson Imaging; 2012 Nov; 36(5):1060-71. PubMed ID: 23090917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium tissue deposition in brain and bone.
    Murata N; Murata K; Gonzalez-Cuyar LF; Maravilla KR
    Magn Reson Imaging; 2016 Dec; 34(10):1359-1365. PubMed ID: 27720805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
    Layne KA; Dargan PI; Archer JRH; Wood DM
    Br J Clin Pharmacol; 2018 Nov; 84(11):2522-2534. PubMed ID: 30032482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of Gadolinium-based Contrast Agent after Leaking into the Cerebrospinal Fluid: Comparison between the Cerebral Cisterns and the Lateral Ventricles.
    Ohashi T; Naganawa S; Iwata S; Kuno K
    Magn Reson Med Sci; 2021 Jun; 20(2):175-181. PubMed ID: 32641590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium contrast agents - are they really safe?
    Malikova H; Holesta M
    J Vasc Access; 2017 Mar; 18(Suppl. 2):1-7. PubMed ID: 28362042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.